Teva Pharmaceutical Industries controversies
Controversies tied to this brand in public sources. A listing is not a finding of fault.
Back to profile7 entries
2023
Generic-drug price-fixing investigation and penalty
Teva was involved in United States criminal antitrust proceedings concerning alleged coordination to fix prices for generic medicines. The company paid a major penalty in 2023, making the matter one of the most significant legal controversies in its corporate history.
2022
Teva reaches Texas opioid claims settlement
Settlement
Teva Pharmaceutical Industries reached a $225 million settlement to resolve claims brought by Texas that it fueled the opioid epidemic through improper marketing of addictive pain medications. According to the report, Teva did not admit wrongdoing as part of the settlement. The event was reported on February 7, 2022.
Teva reached a $225 million settlement to resolve Texas claims that it fueled the opioid epidemic through improper marketing of addictive pain medications. The report says Teva did not admit wrongdoing as part of the settlement.
Stated objective. The settlement was to resolve claims brought by Texas.
Source excerpt
Teva Pharmaceutical Industries has reached a settlement worth $225 million to resolve claims the drugmaker fueled an opioid epidemic in Texas by improperly marketing addictive pain medications, the state's attorney general said on Monday, according to Reuters.
Teva did not admit wrongdoing as part of Monday's settlement, according to Reuters.
2022
Teva settles investor price-fixing lawsuit
Settlement
Teva settled a US investor class action over alleged price fixing, agreeing to pay $420 million without admitting wrongdoing. Teva denied the claims; the lawsuit followed an investigation by US authorities into alleged price fixing in the generic drugs industry.
Company response
Denial — Teva
Teva will pay $420 million, without admitting wrongdoing, and it denies the claims.
Source excerpt
Teva will pay $420 million, without admitting wrongdoing, and it denies the claims.
Now, Teva has also settled a class action filed against it by investors in the US over the price fixing affair in which the company was allegedly involved.
Teva Pharmaceutical Industries Ltd. has agreed to pay $420 million to settle shareholder litigation alleging the company hid an anti-competitive scheme to fix the price of generic drugs.
2021
Mylan sues Teva over alleged Copaxone competition restraints
Lawsuit filed
Mylan Pharmaceuticals filed a federal lawsuit against Teva, alleging that Teva used tactics to delay competition for its multiple sclerosis drug Copaxone. The allegations are not presented as a court determination, and Teva had not yet responded.
Source excerpt
With the suit just filed, Teva has not yet had time to file a response.
Mylan alleges that Teva used various tactics to delay competition and maintain its monopoly on Copaxone, costing the U.S. healthcare system billions in excess spending.
Morgantown-based Mylan Pharmaceuticals—not its parent Viatris—filed the suit in U.S. District Court for the District of New Jersey against Teva and several of its subsidiaries.
2020
U.S. government sues Teva over alleged Copaxone kickbacks
Lawsuit filed
The U.S. Department of Justice sued Teva Pharmaceutical Industries under the Federal False Claims Act. The lawsuit alleges that Teva companies used purportedly independent foundations to pay Medicare co-pays for Copaxone patients in violation of the Anti-Kickback Statute. The allegations are not presented as a court finding.
The U.S. Department of Justice sued Teva under the Federal False Claims Act. The lawsuit alleges that Teva companies used purportedly independent foundations to pay Medicare co-pays for Copaxone patients in violation of the Anti-Kickback Statute; the allegations are not presented as a court finding.
Source excerpt
The lawsuit claims that Teva paid two third-party foundations more than $300 million to cover Medicare co-payment obligations of Copaxone patients.
According to the lawsuit, Teva Pharmaceuticals USA Inc. and Teva Neuroscience Inc. illegally paid the Medicare co-pays for their multiple sclerosis product, Copaxone, through purportedly independent foundations that the companies used as conduits in violation of the Anti-Kickback Statute.
Teva Pharmaceutical Industries Ltd. (TEVA) has been sued by the U.S. Department of Justice under the Federal False Claims Act.
2020
EU fines Teva over generic modafinil delay agreement
Fine or penalty
In a controversy noted in 2020, the European Union fined Teva Pharmaceutical Industries after the European Commission stated that Teva had breached EU antitrust rules. According to the Commission, Teva agreed with Cephalon to keep a cheaper generic version of the drug modafinil off the market. The Commission's position was that this agreement prevented the lower-priced generic modafinil from reaching the market, in violation of EU competition rules. The fine was imposed by the European Union on that basis. The event concerns the antitrust finding and penalty announced by the EU regarding the agreement over generic modafinil.
The European Union fined Teva after the European Commission said Teva breached EU antitrust rules by agreeing with Cephalon to keep a cheaper generic modafinil drug off the market.
Source excerpt
The European Commission said Teva was in breach of EU antitrust rules after it effectively agreed with drug-maker Cephalon, a company it now owns, to keep the cheaper drug off of the market.
European Union regulators on Thursday fined Israeli drug-maker Teva for colluding to delay a cheaper generic version of modafinil, a blockbuster sleep disorder drug, AFP reports.
2019
Criticism over vincristine discontinuation
Teva faced criticism after deciding to discontinue vincristine in the United States. Because the medicine is used in treatment regimens for many childhood cancers, the decision prompted concern about shortages and the responsibilities of manufacturers of essential medicines.